VX‐509 (Decernotinib), an Oral Selective JAK‐3 Inhibitor, in Combination With Methotrexate in Patients With Rheumatoid Arthritis
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Objective: To assess the efficacy and safety of decernotinib (VX‐509), an oral selective inhibitor of JAK‐3, in patients with rheumatoid arthritis (RA) in whom the response to methotrexate treatment was inadequate. Methods: In this 24‐week, double‐blind, randomized phase IIb study, 358 patients with active RA received either placebo (n = 71) or VX‐509 at dosages of 100 mg/day (n = 71), 150 mg/day (n = 72), 200 mg/day (n = 72), or 100 mg twice daily (n = 72). Primary measures of efficacy at week 12 were the response rate according to the American College of Rheumatology 20% improvement criteria (ACR20) and change from baseline in the Disease Activity Score in 28 joints using the C‐reactive protein level (DAS28‐CRP). Results: At week 12, the ACR20 response rates were 46.5%, 66.7%, 56.9%, and 68.1% in the groups receiving VX‐509 at dosages of 100 mg/day, 150 mg/day, 200 mg/day, and 100 mg twice daily, respectively, and 18.3% in the placebo group (P < 0.001 for all comparisons). At week 12, the mean change from baseline in the DAS28‐CRP was significantly greater in each VX‐509 group compared with the placebo group (P < 0.001). Improvements were maintained at week 24, as shown by the ACR20, ACR50, and ACR70 response rates and mean change from baseline in the DAS28‐CRP. The most common adverse event in the VX‐509 group was headache (8.7%), and elevated levels of transaminases, lipoproteins, and creatinine were observed. Conclusion: VX‐509 significantly improved the signs and symptoms of RA at weeks 12 and 24 compared with the placebo group when it was administered in combination with methotrexate. Safety signals included infection and increases in liver transaminase and lipid levels.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Janus kinases in immune cell signaling
Ghoreschi, K., Laurence, A., & O’Shea, J. J. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00754.x · Cited by 1,149 · cited 2×
“Completed original dosing (n=17) Completed original dosing (n=44) Completed original dosing (n=47) Completed original dosing (n=51) Discontinued (n=13) • Adverse event (6) • Refused further dosing (2) • Lost to follow-up (2) • Did not meet eligibility criteria (1) • Physician decision (1) • Other (1) Discontinued (n=9…”
Background
Cited by
The JAK/STAT signaling pathway: from bench to clinic
Hu, X., li, J., Fu, M., Zhao, X., & Wang, W. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00791-1 · Cited by 2,633
JAK inhibition as a therapeutic strategy for immune and inflammatory diseases
Schwartz, D. M., Kanno, Y., Villarino, A., Ward, M., Gadina, M., & O'Shea, J. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.201 · Cited by 1,266
Banerjee, S., Biehl, A., Gadina, M., Hasni, S., & Schwartz, D. M. (2017) · Drugs · doi:10.1007/s40265-017-0701-9 · Cited by 1,206
“In addition, adverse effects of this drug included elevations in lipid parameters [80, 132, 160].”
BackgroundRamiro, S., Gaujoux-Viala, C., Nam, J. L., Smolen, J. S., Buch, M., Gossec, L., van der Heijde, D., Winthrop, K., & Landewé, R. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204575 · Cited by 701
Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer
Xue, C., Yao, Q., Gu, X., Shi, Q., Yuan, X., Chu, Q., Bao, Z., Lu, J., & Li, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01468-7 · Cited by 699
Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases
Schwartz, D. M., Bonelli, M., Gadina, M., & O'Shea, J. J. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2015.167 · Cited by 648
Banerjee, S., Biehl, A., Gadina, M., Hasni, S., & Schwartz, D. M. (2017) · Drugs · doi:10.1007/s40265-017-0736-y · Cited by 590
The emerging safety profile of JAK inhibitors in rheumatic disease
Winthrop, K. L. (2017) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2017.23 · Cited by 590
Signaling pathways in rheumatoid arthritis: implications for targeted therapy
Ding, Q., Hu, W., Wang, R., Yang, Q., Zhu, M., Li, M., Cai, J., Rose, P., Mao, J., & Zhu, Y. Z. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01331-9 · Cited by 478
Erratum: JAK inhibition as a therapeutic strategy for immune and inflammatory diseases
Schwartz, D. M., Kanno, Y., Villarino, A., Ward, M., Gadina, M., & O'Shea, J. J. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.267 · Cited by 394
A Comprehensive Overview of Globally Approved JAK Inhibitors
Shawky, A. M., Almalki, F. A., Abdalla, A. N., Abdelazeem, A. H., & Gouda, A. M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14051001 · Cited by 349
Current and future status of JAK inhibitors
McLornan, D. P., Pope, J. E., Gotlib, J., & Harrison, C. N. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00438-4 · Cited by 305
The role of the JAK/STAT signal pathway in rheumatoid arthritis
Malemud, C. J. (2018) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x18776224 · Cited by 302
JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis
Fragoulis, G. E., McInnes, I. B., & Siebert, S. (2019) · Rheumatology · doi:10.1093/rheumatology/key276 · Cited by 296
Kerschbaumer, A., Sepriano, A., Smolen, J. S., van der Heijde, D., Dougados, M., van Vollenhoven, R., McInnes, I. B., Bijlsma, J. W. J., Burmester, G. R., de Wit, M., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-216656 · Cited by 293
Self-citationClinical significance of Janus Kinase inhibitor selectivity
Choy, E. H. (2019) · Rheumatology · doi:10.1093/rheumatology/key339 · Cited by 285
Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases
Virtanen, A. T., Haikarainen, T., Raivola, J., & Silvennoinen, O. (2019) · BioDrugs · doi:10.1007/s40259-019-00333-w · Cited by 281
Sepriano, A., Kerschbaumer, A., Smolen, J. S., van der Heijde, D., Dougados, M., van Vollenhoven, R., McInnes, I. B., Bijlsma, J. W., Burmester, G. R., de Wit, M., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-216653 · Cited by 275
Self-citation
Metadata
- Authors
- Genovese, M. C., van Vollenhoven, R. F., Pacheco‐Tena, C., Zhang, Y., & Kinnman, N.
- Venue
- Arthritis & Rheumatology
- Publisher
- Wiley
- Published
- 2015-12-23
- Volume
- 68
- Issue
- 1
- Pages
- 46-55
- ISSN
- 2326-5191 (ISSN-L)
- 2326-5205
- OpenAlex
- W1916256274
- Cited by
- 128
- References
- 1
- FWCI
- 8.26
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.